RxDoctor Payments Data

Corazon Medina, MD

Internal Medicine · Anaheim, CANPI 1083883904

Payments from drug & device makers

$1,534in general payments, 2019–2025

Across 92 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$615
  • GSK$306
  • Kowa Pharmaceuticals America, Inc.$256
  • Pfizer$192
  • AstraZeneca$50
  • Jazz Pharmaceuticals Inc.$38
  • plus $77 from 4 others

What the payments were for

  • Food & beverage$1,342100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,534 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$28,075
Medicare patients
87
Services billed
622

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide171$180,747
FarxigaDapagliflozin Propanediol162$153,328
JardianceEmpagliflozin146$152,250
Trelegy ElliptaFluticasone/Umeclidin/Vilanter106$70,876
EliquisApixaban59$53,951
JanuviaSitagliptin Phosphate63$51,629
TradjentaLinagliptin52$38,437
RybelsusSemaglutide29$34,956
TrulicityDulaglutide21$30,021
Lantus SolostarInsulin Glargine,hum.Rec.Anlog95$14,631
XareltoRivaroxaban19$14,413
Fluticasone-SalmeterolFluticasone Propion/Salmeterol53$12,129
Wixela InhubFluticasone Propion/Salmeterol76$11,835
GlyxambiEmpagliflozin/Linagliptin17$10,487
LinzessLinaclotide15$10,009

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$615$215,703200 claims
Boehringer IngelheimJardiance, Tradjenta, Glyxambi$19$201,175215 claims
AstraZenecaFarxiga$50$153,328162 claims
GSKTrelegy Ellipta, Breo Ellipta$306$77,838123 claims
PfizerEliquis$192$53,95159 claims
Kowa Pharmaceuticals America, Inc.Livalo$256$6,20017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Anaheim

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →